I Hate Dialysis Message Board
Dialysis Discussion => Dialysis: News Articles => Topic started by: okarol on November 03, 2008, 12:33:45 PM
-
NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy
Patient adoption of daily home therapy continues to grow; Positive data
supports broader acceptance within ESRD community.
LAWRENCE, Mass., Nov. 3 /PRNewswire-FirstCall/ -- NxStage Medical, Inc.
(Nasdaq: NXTM), a leading manufacturer of innovative dialysis products,
today announced that 3,000 end-stage renal disease (ESRD) patients are now
prescribed to receive therapy using its NxStage(R) System One(TM), the
first truly portable home hemodialysis machine. This latest milestone
represents 35% growth in patient adoption since the end of 2007. The
NxStage System One is now available at hundreds of dialysis centers in
markets throughout the United States.
"We are pleased by the continuing, annual increase in patient adoption
of daily home hemodialysis (DHD) with the NxStage System One," said Jeff
Burbank, President and Chief Executive Officer of NxStage Medical, Inc.
"This validates our strategy to build sustained growth by working closely
with patients and their care-providers in key markets while continuing to
broaden nationwide access. It is exciting to see how DHD with the NxStage
System One is benefiting the lives of patients. The latest significant
evidence of this impact are the just-released interim results of our
landmark FREEDOM study, which show that NxStage's DHD therapy significantly
improves patients' health-related quality-of-life in terms of recovery
time, depressive symptoms and overall health-related quality-of-life, in
comparison with conventional, thrice-weekly in-center hemodialysis
treatment."
The NxStage System One is the first truly portable hemodialysis system
cleared for home use by the FDA. Unlike traditional dialysis equipment, the
System One plugs into a standard electrical outlet, requires no special
infrastructure to operate and is easy to use by trained patients
accompanied by their trained partners. Rather than commuting to and from a
dialysis clinic three times per week for scheduled treatment sessions
lasting three to four hours, patients who use the NxStage System One have
the personal freedom to conduct prescribed treatments at home on their own
schedule and to bring the System with them when they travel. The System One
works in concert with NxStage's PureFlowTM SL dialysate preparation system,
a compact, easy-to-use system that prepares high-purity dialysate from
regular tap water, helping to make daily home hemodialysis even more
practical and accessible to patients. The PureFlow SL eliminates the need
for bagged dialysate in the home, while still allowing patients to use
bagged fluids when they travel.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company,
headquartered in Lawrence, Massachusetts, USA, that develops, manufactures
and markets innovative products for the treatment of End Stage Renal
Disease (ESRD) and acute kidney failure. For more information on NxStage
and its products, please visit the company's website at
http://www.nxstage.com.
About End-Stage Renal Disease
End-stage renal disease is the permanent failure of the kidneys to
filter the body's wastes. It is most commonly caused by diabetes,
hypertension, or genetic disorders. In order to survive, ESRD patients must
use some form of therapy to replace the function of the kidneys for the
rest of their lives. Currently, over 450,000 patients in the United States
suffer from ESRD, and the costs of treating ESRD patients are over $20
billion annually in the U.S. Due to increases in diabetes, hypertension,
and the aging of the U.S. population, those figures are projected to double
within the next 10-15 years. The most common form of kidney replacement
therapy in the United States today is hemodialysis, which is used by over
350,000 patients. The great majority of these patients are treated with
conventional, in-center hemodialysis, in which they must travel to a nearby
dialysis center three times per week, where they are connected to dialysis
machines for treatments lasting approximately three to four hours, to
cleanse their blood.
About Hemodialysis
Today, most patients undergo hemodialysis therapy three times a week in
outpatient dialysis centers. This differs significantly from the 24/7
workings of the naturally functioning kidney. Increasingly, clinicians and
patients have recognized opportunities for therapy improvements with more
frequent, or daily, dialysis. Hundreds of clinical papers have reported on
the health and quality of life benefits of hemodialysis done more
frequently. The reported benefits include reduced hypertension, reduced
cardiac strain and left ventricular hypertrophy, reduced amyloid disease,
and improved anemia status, appetite, and quality of life, including the
ability to return to work. A summary of the literature discussing these
benefits can be found on NxStage's website, http://www.nxstage.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. All statements
contained in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended to
identify forward-looking statements. Actual results may differ materially
from those indicated by these forward-looking statements as a result of
various important factors including, but not limited to: expected growth in
home daily hemodialysis and market acceptance of the NxStage System One,
anticipated growth in ESRD patient numbers, the anticipated impact and
results of the FREEDOM study and other factors that are discussed in
NxStage's filings with the Securities and Exchange Commission, including
the Quarterly Report on Form 10-Q for the quarter ended June 30, 2008.
NxStage is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor Relations Contact
Kristen Sheppard
NxStage Medical, Inc.
ir@nxstage.com
978-332-5923
Media Contact
Jim Weinrebe
Schwartz Communications, Inc.
nxstage@schwartz-pr.com
781-684-0770
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-03-2008/0004916823&EDATE=